HRPP/IRB Newsletter

September 2024

Contact the IRB

Contact IRB Reliance Team

Contact DRAFT Services

Contact Quality Assurance and Evaluation Team

Contact For ClinicalTrials.gov Support

Rutgers University has earned full accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Learn more.]=

Upcoming Events

Click here for the agenda.

Register by scanning the QR code or clicking the button below:

Register Now

Updates to the eCOI+ System

Based on valuable feedback from users, we have incorporated significant enhancements and functionality to the eCOI+, including:

 

  • A portal upgrade by migrating from Portal version 9.06 to 10.0.7.
  • A new start-up company module that will streamline the review of start-up company disclosures.
  • A new user profile section.

 

Portal 10.0.7 introduces a more modern, intuitive, and user-friendly experience. Its key improvements include redesigned workspace components, personalizing project listings, and viewing search results directly on a page instead of a separate slide-in window.



The updated eCOI+ application is live and can be accessed by visiting https://eCOI.Rutgers.edu.

 

For additional help and support, please review our Quick Guides or view Conflict of Interest FAQs (Frequently Asked Questions).

Get to Know the eIRB+ Application Types

Second in our series on eIRB+ application types is the eIRB+ application for minimal risk research titled “Research Protocol Study (minimal risk) - Expedited/Exempt.”  


Have you seen the new eIRB+ application for research projects involving minimal risk activities?

Choosing the “Research Protocol Study (minimal risk) - Expedited/Exempt” application routes the study through the exempt or expedited review process in eIRB+. This means that a designated reviewer (or reviewers) will review the application without the need for discussion at a convened, full board meeting of the IRB. The “Research Protocol Study (minimal risk) - Expedited/Exempt” application type should only be used for minimal risk research.


Note: The IRB reserves the right to request that the research team change the application type depending on the IRB’s analysis of the application.   


What does minimal risk mean?   

Minimal Risk means “the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests” (45 CFR 46.102(j); 21 CFR 56.102(i)). 


When should this application be used? 

This application should only be used when your research creates/analyzes new information gathered through interaction or intervention with living individuals and the research is considered minimal risk.


This application should also be used when your research is analyzing biospecimens created by other research or originally created for non-research purposes and the research is considered minimal risk. 


Can you give me some examples of minimal risk research?  

The following are examples of types of research that may be submitted to the IRB under this application type if the probability and magnitude of harm or discomfort anticipated in the research are not greater, in and of themselves, than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests: 

  • Survey research 
  • Interview or Focus Group research 
  • Research involving benign behavioral interventions (e.g. having the subjects play an online game, having them solve puzzles under various noise conditions, or having them decide how to allocate a nominal amount of received cash between themselves and someone else) 
  • Observation of human subject activities 
  • Research on regular and special education instructional strategies 
  • Research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods  
  • Research involving analysis of biospecimens collected under a prior research activity by other research or originally created for non-research purposes (left over specimens from a routine medical procedure) 
  • Biospecimens collected in non-invasive ways (e.g. urine sample, hair and nail clippings) 
  • Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves  
  • Taste and food quality evaluation and consumer acceptance studies 

 

May I use this application for clinical research involving drugs or medical devices?  

It depends. This application should only be used if your clinical study of drugs and / or medical devices meets one of the following two conditions: 

  1. Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review). or 
  2. Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling. 

 

May I use this application for research that involves collection of blood from human subjects?   

It depends. This application should only be used if your research involves the collection of blood samples by finger stick, heel stick, ear stick, or venipuncture and the following criteria are met: 

  1. Collection from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or 
  2. Collection from other adults and children, considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week. 

 

Learn more about the Research Protocol Study (minimal risk) - Expedited/Exempt eIRB+ application. 

eIRB+ PDF Quick Guides for each of the eIRB+ initial submission types are available.


These step-by-step Quick Guides provide overviews, screenshots, and tips for the eIRB+ application.

 

eIRB+ PDF Quick Guides

Consult with HRPP/IRB Subject Matter Experts

Virtual Institutional Review Board (IRB) Office Hours


DRAFT (Document Revision And Feedback Team) Services hosts IRB Office Hours weekly.

When:

  • Tuesdays, 1 – 1:30 pm (with IRB Reliance Team)


  • Thursdays, 10 – 10:30 am


Where:

Office Hours Zoom Link

Passcode: 133269



More information on what to expect during Virtual IRB Office Hours.

The mission of the Document Review and Feedback Team (DRAFT) is to improve IRB submission outcomes by recommending and educating study teams on HRPP/IRB considerations and best practices through pre-reviews and consultations.


Learn more about DRAFT.


The IRB Reliance Team provides subject matter expertise and consultations on the IRB requirements for collaborative research.


These subject matter experts are adept at assisting study teams with navigating IRB requirements for engaging in multi-institutional research.


Learn more about Reliance.

Workshop and Training Opportunities

Attend a virtual eIRB+ Workshop to learn more about the updates to our submission platform and business processes.



eIRB+ Workshop sessions offer a comprehensive walkthrough of updated features, step-by-step application tutorials, and an opportunity to address any questions you may have.


Register now on the Course Registration System to secure your spot in upcoming training sessions. Multiple sessions will be available weekly throughout each month/semester.

Register for an eIRB+ Workshop

ClinicalTrials.gov Update

On August 28, 2024, the ClinicalTrials.gov Protocol Registration and Results System (PRS) Beta will become the primary website for protocol registration and management of study records. New features of the Modernized PRS website include: 

  • An enhanced, user-friendly interface with a fresh color scheme, larger fonts, and clearly identifiable sections and labels. 
  • Improved navigation between study record sections and modules through the implementation of tabs at the top of the page and a left-hand menu. 
  • Accessible on-screen guidance and help content with relevant data element definitions. 
  • A redesigned Record List that allows you to select columns, customize the view, save your customized view, and export all columns or only the displayed columns to .xlsx or .csv. 

 

In addition, data submitters can use the modernized Record Summary page to view a summary of the quality-assurance/quality-control review comments, as well as access the comments directly within the relevant protocol registration modules. Read the latest NLM Technical Bulletin and log into PRS Test to learn more about the new features of the Modernized PRS (PRS Beta). 

 

The Modernized PRS website will continue to be expanded and improved. To ensure an optimal user experience, you are encouraged to submit comments and suggestions using the yellow feedback button at the bottom right corner of the screen to let NLM know what you think of the Modernized PRS.  

 

More information about the transition to the Modernized PRS can be found in the Modernization Transition Top Questions. For additional information about modernization-related events and resources, visit the ClinicalTrials.gov Modernization webpage


Recommended Reading

Congratulations to Institutional Review Board (IRB) / Human Research Protection Program (HRPP) Director Swapnali Chaudhari, whose article Navigating the Grey: Balancing Research Compliance and Innovation has been published in the August issue of NCURA Magazine.


This piece highlights the challenge researchers face with regards to "the ethical use of AI in their research while pushing the boundaries of innovation."


Click here to read the full issue. Swapnali's article appears on page 7.ttps://lnkd.in/efW9tADz

Contact Us / Jason Lin


Visit our webpage

Facebook  Twitter  Linkedin